DK3094731T3 - Saccharide-modified nucleic acid molecules - Google Patents

Saccharide-modified nucleic acid molecules Download PDF

Info

Publication number
DK3094731T3
DK3094731T3 DK15700464.9T DK15700464T DK3094731T3 DK 3094731 T3 DK3094731 T3 DK 3094731T3 DK 15700464 T DK15700464 T DK 15700464T DK 3094731 T3 DK3094731 T3 DK 3094731T3
Authority
DK
Denmark
Prior art keywords
saccharide
nucleic acid
acid molecules
modified nucleic
modified
Prior art date
Application number
DK15700464.9T
Other languages
Danish (da)
Inventor
Thomas Carell
Original Assignee
Baseclick Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baseclick Gmbh filed Critical Baseclick Gmbh
Application granted granted Critical
Publication of DK3094731T3 publication Critical patent/DK3094731T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DK15700464.9T 2014-01-15 2015-01-15 Saccharide-modified nucleic acid molecules DK3094731T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14151255 2014-01-15
PCT/EP2015/050685 WO2015107115A1 (en) 2014-01-15 2015-01-15 Saccharide-modified nucleic acid molecules

Publications (1)

Publication Number Publication Date
DK3094731T3 true DK3094731T3 (en) 2019-08-05

Family

ID=49989536

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15700464.9T DK3094731T3 (en) 2014-01-15 2015-01-15 Saccharide-modified nucleic acid molecules

Country Status (14)

Country Link
US (1) US10751425B2 (en)
EP (1) EP3094731B1 (en)
JP (1) JP6584412B2 (en)
CN (1) CN105899666B (en)
BR (1) BR112016014162A2 (en)
DK (1) DK3094731T3 (en)
ES (1) ES2742102T3 (en)
HR (1) HRP20191471T1 (en)
HU (1) HUE045086T2 (en)
LT (1) LT3094731T (en)
PL (1) PL3094731T3 (en)
PT (1) PT3094731T (en)
SI (1) SI3094731T1 (en)
WO (1) WO2015107115A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CN109562185A (en) 2016-06-02 2019-04-02 赛诺菲 The new conjugate of medicament and the part that albumen can be incuded in conjunction with glucose
WO2018109138A1 (en) * 2016-12-14 2018-06-21 University College Cork - National University Of Ireland, Cork Cyclodextrin conjugates
EP3728602A1 (en) * 2017-12-21 2020-10-28 baseclick GmbH Click-modified mrna
US12065458B2 (en) 2018-02-17 2024-08-20 Arrowhead Pharmaceuticals, Inc. Trialkyne linking agents and methods of use
JP7420727B2 (en) * 2018-02-17 2024-01-23 アローヘッド ファーマシューティカルズ インコーポレイテッド Trialkyne binder and method of use
CN114514039A (en) * 2019-08-05 2022-05-17 宝利普拉斯生物转染公司 Composition for transfecting a nucleic acid molecule into a cell comprising a heterocyclic compound grafted to a cationic polymer and uses thereof
CN111041025B (en) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 mRNA targeting molecule based on combination of N-acetylgalactosamine polypeptide and preparation method thereof
CN112111524B (en) * 2020-01-10 2024-02-27 深圳瑞吉生物科技有限公司 Preparation method of mRNA-GalNAc targeting molecule, in-vivo delivery system and application thereof
CN111744019B (en) * 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 Mannose-based mRNA targeted delivery system and application thereof
WO2022094609A1 (en) * 2020-10-30 2022-05-05 Speer Tod Oligonucleotide-based therapeutics and uses thereof
TW202304472A (en) * 2021-04-23 2023-02-01 美商格納生物公司 Glycan modified nucleic acids, methods of preparation, and therapeutic uses
EP4401786A1 (en) * 2021-09-13 2024-07-24 GanNA Bio, Inc. Glycan conjugate compositions and methods
WO2023233395A1 (en) * 2022-05-30 2023-12-07 Nurexone Biologic Ltd. Compositions and methods for loading extracellular vesicles
CN115487308B (en) * 2022-09-29 2024-09-27 北京大学 Antisense nucleic acid glycosyl conjugate, preparation method thereof and application thereof in liver cancer treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2352509T3 (en) 2005-05-02 2011-02-21 Baseclick Gmbh NEW MARKING STRATEGIES FOR THE SENSITIVE DETECTION OF ANALYTES.
JP2007044012A (en) * 2005-08-12 2007-02-22 Konan Gakuen Method for controlling moisture evaporation of leaf and method for improving drought resistance of plant
WO2009024977A2 (en) * 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
CA3043911A1 (en) * 2007-12-04 2009-07-02 Arbutus Biopharma Corporation Targeting lipids

Also Published As

Publication number Publication date
HUE045086T2 (en) 2019-12-30
HRP20191471T1 (en) 2019-11-15
US10751425B2 (en) 2020-08-25
SI3094731T1 (en) 2019-10-30
US20160333364A1 (en) 2016-11-17
PL3094731T3 (en) 2019-10-31
EP3094731B1 (en) 2019-07-17
CN105899666A (en) 2016-08-24
CN105899666B (en) 2020-10-09
WO2015107115A1 (en) 2015-07-23
JP2017504322A (en) 2017-02-09
JP6584412B2 (en) 2019-10-02
EP3094731A1 (en) 2016-11-23
PT3094731T (en) 2019-09-04
ES2742102T3 (en) 2020-02-13
LT3094731T (en) 2019-10-25
BR112016014162A2 (en) 2018-01-09

Similar Documents

Publication Publication Date Title
DK3341482T3 (en) ARTIFICIAL NUCLEIC ACID MOLECULES
DK3433368T3 (en) TRANSREPLICATING RNA
SG11201704681QA (en) Artificial nucleic acid molecules
DK3234132T3 (en) LIGAND-MODIFIED DOUBLE-STRUCTED NUCLEIC ACIDS
DK4023755T5 (en) ARTIFICIAL NUCLEIC ACID MOLECULES FOR ENHANCED PROTEIN EXPRESSION
DK3094731T3 (en) Saccharide-modified nucleic acid molecules
DK3129487T3 (en) IMPROVED NUCLEIC ACID CONSTRUCTIONS FOR EUKARYOT GENEPRESSION
DK3188836T3 (en) DNA SYNTHESIS
DK3167044T3 (en) microfluidic
DK3006072T3 (en) Karadgang
DK3351633T3 (en) Antisense nucleic acid
DK3105250T3 (en) MULTISPECIFIC IGA BINDING MOLECULES
DK3341479T3 (en) LNA-G Process
DK3242685T3 (en) CXCR4-BINDING MOLECULES
DK3110442T3 (en) MODIFIED MENINGOKOK-FHBP POLYPEPTIDER
DE112015001664A5 (en) Betätigungsaktuator
DK2952752T3 (en) Deflection-pipe bending
DE112015005041A5 (en) GARGERÄTEVORRICHTUNG
DK2988086T3 (en) HEATER
GB201415674D0 (en) Nucleic acid analysis
DE102014000623A8 (en) Halbhohlnietelement
DK3009858T3 (en) SKYRADAR
DK3119887T3 (en) Improved short interfering ribonucleic acid molecules
DE112015001633A5 (en) Betätigungsaktuator
DE112014006652A5 (en) steering support